Zhejiang University Announces Intended Transfer of Four Exosome-Related Patents for RMB 600,000

From December 31, 2025, to January 14, 2026, Zhejiang University publicly disclosed information regarding the transfer of a major patent achievement, with600,000 yuanat a proposed transfer priceFour Exosome-Related Technology PatentsThis patent transfer covers four high-demand biomedical fields: wound repair, skin anti-aging, superficial tumor treatment, and peripheral nerve repair. Leveraging the innovative approach of “natural ingredients + multi-technology synergy,” it provides novel solutions to many long-standing clinical pain points and injects new vitality into the industrial application of exosome technology.

In the fields of clinical treatment and skin health management,Numerous challenges have long plagued patients, healthcare providers, and researchers. In the field of wound healing, chronic wounds and deep tissue injuries represent a major clinical challenge. These wounds often exhibit significantly prolonged healing cycles due to disrupted local inflammatory microenvironments, insufficient stem cell recruitment, and slow angiogenesis, making them highly prone to sequelae such as hypertrophic scarring and impaired tissue function. The repair of peripheral nerve injuries is even more daunting; axonal regeneration proceeds extremely slowly, and complete remyelination is difficult to achieve. Clinical data indicate that the recovery rates of motor and sensory functions in patients with such injuries<30%In contrast, existing treatment options are limited: traditional medical dressings provide only basic wound protection and cannot actively modulate inflammatory responses or induce directed migration of stem cells; meanwhile, commercially available nerve repair drugs and scaffold materials struggle to achieve simultaneous regeneration of neural structure and function, failing to meet the actual demands of clinical practice.

In the field of skin health and tumor treatment,Significant bottlenecks remain to be overcome. The essence of skin aging lies in decreased fibroblast activity, reduced collagen fiber synthesis, and exacerbated oxidative stress damage. Most existing anti-aging products rely on chemically synthesized ingredients, whose effects are limited to epidermal moisturization. They struggle to penetrate the stratum corneum—the natural barrier of the skin—to achieve deep, cellular-level repair. Furthermore, some products carry a risk of sensitization, potentially causing long-term harm to the skin. For superficial skin tumors such as melanoma, traditional chemotherapy and radiotherapy suffer from poor targeting. While destroying tumor cells, these treatments readily damage surrounding healthy skin tissue, leading to side effects such as skin ulceration and hyperpigmentation. They may also induce drug resistance in tumor cells, resulting in disease recurrence. These clinical challenges collectively underscore an urgent demand for biomedical materials that offer “precise regulation, natural low toxicity, and multi-effect synergy.”

The four patents transferred by Zhejiang University this time are precisely grounded in these clinical needs, withExosome Technologyas the core, to create highly differentiated technical advantages and innovative highlights. In the selection of active ingredients, the patent innovatively adoptsTraditional Chinese Medicine Exosomes, Pueraria lobata ExosomesAs the core carrier of therapeutic efficacy, these natural-origin exosomes, compared to traditional chemically synthesized drugs, not only significantly enhance biocompatibility and safety but also retain the advantages of multi-component synergistic effects characteristic of Traditional Chinese Medicine (TCM). They can simultaneously achieve multiple biological effects, including anti-inflammation, promotion of angiogenesis, acceleration of tissue repair, and anti-skin aging. At the level of technological integration, the patent overcomes the limitations of single exosome delivery technologies by organically combining them with cutting-edge approaches such as photosensitive therapy, piezoelectric bio-stimulation, and stem cell recruitment, thereby constructing a multifunctional, integrated biomedical material system.

Specifically,Wound Repair Dressing Loaded with Traditional Chinese Medicine-Derived Exosomes,Instant fabrication can be achieved via in situ UV crosslinking, enabling conformal coverage of the wound while simultaneously modulating inflammation and inducing stem cell differentiation;Peripheral Nerve Repair Dressing with Piezoelectric Stimulation Function,It can leverage the mechanical response of polyvinylidene fluoride (PVDF) piezoelectric films to continuously release mild electrical potential stimulation, synergizing with traditional Chinese medicine-derived exosomes to accelerate neural axon regeneration and myelin sheath repair;Exosome Formulations Targeting Superficial Skin Tumors,This approach leverages the photothermal effect of the photosensitizer indocyanine green (ICG) to achieve a synergistic therapeutic model combining “exosome-targeted delivery” with “precise photothermal ablation,” thereby significantly enhancing the efficiency of tumor treatment. Furthermore,Transdermal Modification Technology, its application has further addressed the industry pain point that traditional topical formulations struggle to penetrate the stratum corneum barrier, significantly enhancing the skin penetration and bioavailability of active ingredients, thereby enabling drugs to reach the lesion site directly and exert their therapeutic effects.

From the perspectives of commercialization prospects and market value, these four patented technologies demonstrate significant development potential. On the medical side, dressings for trauma repair and peripheral nerve repair can directly address the clinical needs of multiple departments in public hospitals, including trauma, orthopedics, burn, and hand and foot surgery, thereby precisely resolving therapeutic challenges associated with chronic wounds and nerve injury repair. The exosome-based photosensitizer formulation targeting superficial skin tumors fills a technological gap in the field of localized precision therapy, reduces the toxic side effects of traditional radiotherapy and chemotherapy, and aligns with the prevailing trend toward minimally invasive and precise cancer treatments. On the consumer side, the transdermally modified Pueraria lobata exosome anti-aging formulation, leveraging its core selling points of natural origin and cellular-level deep repair, can directly enter the high-end medical aesthetics and functional skincare sectors, precisely meeting consumer demand for safe and highly effective anti-aging products.

Notably, the four patents do not exist in isolation; rather, they form a mutually supportive technological matrix. They can be independently developed into various categories of medical products or consumer-grade skincare items, or integrated to build a multi-disciplinary biomedical materials platform, thereby further enhancing the commercial value-added of the technology. As subsequent clinical research advances and product registration applications are progressively implemented, this exosome technology originating from Zhejiang University is poised for rapid industrialization. This will not only generate significant economic benefits for the commercializing parties but also drive technological upgrades in China’s biomedical materials sector, bringing tangible benefits to more patients.